Association between apolipoprotein E gene polymorphism and mild cognitive impairment: a meta-analysis
Yunxia Jiang1, Tao He2, Wenshuai Deng2
1Nursing College of Qingdao University, Qingdao University.
Abstract:
A number of published case-control studies reported that the apolipoprotein E (ApoE) gene polymorphism was associated with the mild cognitive impairment (MCI). However, previous reports still remain conflicting. To estimate the association between ApoE polymorphism and MCI susceptibility, we searched the electronic databases including PubMed, Wanfang, CNKI (China National Knowledge Infrastructure), VIP, and EMBASE to retrieve all available studies. A total of 18 studies with 2,004 cases and 3,705 controls were included in this meta-analysis. The pooled analysis based on selected studies showed that statistically significant risk association was found between ApoE gene polymorphism and MCI in overall population (ε4 vs ε3: odds ratio [OR] =2.38, 95% confidence interval [CI]: 2.11-2.68; ε4/ε4 vs ε3/ε3: OR =4.45, 95% CI: 3.06-6.48; ε2/ε4 vs ε3/ε3: OR =2.57, 95% CI: 1.77-3.73; ε3/ε4 vs ε3/ε3: OR =2.31, 95% CI: 1.99-2.69). However, no significant association was detected in two genetic models: ε2 versus ε3 (OR =0.90, 95% CI: 0.77-1.05) and ε2/ε2 versus ε3/ε3 (OR =0.91, 95% CI: 0.50-1.65). Furthermore, ApoE ε2/ε3 genotype provided a slight protection for MCI in overall population (ε2/ε3 vs ε3/ε3: OR =0.80, 95% CI: 0.66-0.97). In the stratified analysis based on ethnicity, similar results were also observed in Chinese population (significant risk: ε4 vs ε3: OR =2.52, 95% CI: 2.19-2.90; ε4/ε4 vs ε3/ε3: OR =5.45, 95% CI: 3.41-8.70; ε2/ε4 vs ε3/ε3: OR =2.59, 95% CI: 1.74-3.86; ε3/ε4 vs ε3/ε3: OR =2.34, 95% CI: 1.97-2.79; slight protection: ε2/ε3 vs ε3/ε3: OR =0.79, 95% CI: 0.64-0.98; no association: ε2 vs ε3: OR =0.92, 95% CI: 0.78-1.09; and ε2/ε2 vs ε3/ε3: OR =1.04, 95% CI: 0.55-1.99). In summary, this meta-analysis of 5,709 subjects suggested that ApoE ε4 allele was associated with an increased risk of MCI. In addition, ApoE ε2/ε3 genotype provided a slight protection for MCI.
Insights
The apolipoprotein E (ApoE) ε4 allele increases the risk of mild cognitive impairment (MCI). However, the ApoE ε2/ε3 genotype may offer slight protection against MCI, according to this meta-analysis.
Area of Science:
- Genetics
- Neurology
- Epidemiology
Background:
- The apolipoprotein E (ApoE) gene is implicated in lipid transport and has been linked to neurodegenerative diseases.
- Previous studies on the association between ApoE gene polymorphism and mild cognitive impairment (MCI) have yielded conflicting results.
Purpose of the Study:
- To conduct a comprehensive meta-analysis to clarify the association between ApoE gene polymorphism and MCI susceptibility.
- To pool data from multiple case-control studies to achieve a more robust statistical estimation.
Main Methods:
- Systematic literature search of electronic databases (PubMed, Wanfang, CNKI, VIP, EMBASE) for relevant case-control studies.
- Inclusion of 18 studies comprising 2,004 cases and 3,705 controls.
- Meta-analysis performed using various genetic models to assess risk and protective associations.
Main Results:
- The ApoE ε4 allele was significantly associated with an increased risk of MCI in the overall population (e.g., ε4 vs ε3: OR=2.38, 95% CI: 2.11-2.68).
- The ApoE ε2/ε3 genotype showed a slight protective effect against MCI (OR=0.80, 95% CI: 0.66-0.97).
- Similar associations were observed in stratified analyses, including the Chinese population.
Conclusions:
- The ApoE ε4 allele is a significant risk factor for developing MCI.
- The ApoE ε2/ε3 genotype may confer a protective effect against MCI, warranting further investigation.
More Related Videos
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenomics: Identification of New Drug Targets
